![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MCM9 |
Gene summary for MCM9 |
![]() |
Gene information | Species | Human | Gene symbol | MCM9 | Gene ID | 254394 |
Gene name | minichromosome maintenance 9 homologous recombination repair factor | |
Gene Alias | C6orf61 | |
Cytomap | 6q22.31 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q9NXL9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
254394 | MCM9 | CCI_1 | Human | Cervix | CC | 2.67e-04 | 5.28e-01 | 0.528 |
254394 | MCM9 | CCI_2 | Human | Cervix | CC | 2.95e-05 | 5.65e-01 | 0.5249 |
254394 | MCM9 | CCI_3 | Human | Cervix | CC | 9.75e-04 | 4.66e-01 | 0.516 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Cervix | ![]() | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
N_HPV: HPV-infected normal cervix |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00062602 | Cervix | CC | DNA replication | 48/2311 | 260/18723 | 2.70e-03 | 1.85e-02 | 48 |
GO:00323923 | Cervix | CC | DNA geometric change | 21/2311 | 90/18723 | 2.71e-03 | 1.85e-02 | 21 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MCM9 | SNV | Missense_Mutation | novel | c.2855N>T | p.Ser952Ile | p.S952I | Q9NXL9 | protein_coding | tolerated_low_confidence(0.14) | possibly_damaging(0.481) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MCM9 | SNV | Missense_Mutation | novel | c.1600C>A | p.Leu534Met | p.L534M | Q9NXL9 | protein_coding | deleterious(0.03) | probably_damaging(0.992) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MCM9 | SNV | Missense_Mutation | novel | c.569C>T | p.Ser190Phe | p.S190F | Q9NXL9 | protein_coding | deleterious(0) | probably_damaging(0.917) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MCM9 | SNV | Missense_Mutation | novel | c.3218C>T | p.Ser1073Phe | p.S1073F | Q9NXL9 | protein_coding | deleterious_low_confidence(0.03) | benign(0.23) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
MCM9 | SNV | Missense_Mutation | c.2890G>A | p.Ala964Thr | p.A964T | Q9NXL9 | protein_coding | tolerated_low_confidence(0.14) | benign(0.031) | TCGA-AX-A1C5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | SD | |
MCM9 | SNV | Missense_Mutation | novel | c.1814N>G | p.Gln605Arg | p.Q605R | Q9NXL9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
MCM9 | SNV | Missense_Mutation | rs531103567 | c.3319N>T | p.Arg1107Cys | p.R1107C | Q9NXL9 | protein_coding | deleterious_low_confidence(0.02) | benign(0.371) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
MCM9 | SNV | Missense_Mutation | rs9387607 | c.1521N>T | p.Glu507Asp | p.E507D | Q9NXL9 | protein_coding | deleterious(0.03) | probably_damaging(0.944) | TCGA-DF-A2KY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
MCM9 | SNV | Missense_Mutation | rs367896634 | c.395N>A | p.Arg132Gln | p.R132Q | Q9NXL9 | protein_coding | deleterious(0) | benign(0.436) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MCM9 | SNV | Missense_Mutation | rs150953346 | c.2909G>A | p.Arg970His | p.R970H | Q9NXL9 | protein_coding | tolerated_low_confidence(0.2) | benign(0) | TCGA-EC-A24G-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |